Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
- 18 March 2009
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 117 (3), 615-623
- https://doi.org/10.1007/s10549-009-0366-5
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast CancerJournal of Clinical Oncology, 2008
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceEndocrine Reviews, 2008
- A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancerInvestigational New Drugs, 2007
- Intentional and non-intentional non-adherence to medication amongst breast cancer patientsEuropean Journal Of Cancer, 2006
- Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerBritish Journal of Cancer, 2006
- Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology GroupBreast Cancer Research and Treatment, 2005
- A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancerBreast Cancer Research and Treatment, 2005
- Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorJournal of Clinical Oncology, 2004
- Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerEuropean Journal Of Cancer, 2004
- The behavioral dynamics of clinical trialsPreventive Medicine, 1991